Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 78, Issue 5, 2010, Pages 1407-1412

  Li, Gang ^a   Hu, Wei ^b   Wang, Jianhua ^b   Deng, Xia ^a   Zhang, Ping ^a   Zhang, Xuebang ^a   Xie, Congyin ^a   Wu, Shixiu ^a  

^a Department of Radiation Oncology   (China)

^b TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE   (China)

Author keywords

Chemoradiation; EGFR inhibition; Esophageal carcinoma; Radiosensitization

Indexed keywords

ACUTE TOXICITY; CHEMORADIATION; CHEMORADIOTHERAPY; CIS-PLATIN; CONCURRENT CHEMORADIATION; CONCURRENT CHEMORADIOTHERAPY; EGFR INHIBITION; EPIDERMAL GROWTH FACTOR RECEPTORS; ERLOTINIB; ESOPHAGEAL CARCINOMA; LEUCOPENIA; OVERALL SURVIVAL; PACLITAXEL; PHASE II; RADIO-SENSITIZATION; THROMBOCYTOPENIA; TOTAL DOSE;

AMINO ACIDS; ENZYME INHIBITION; PLATINUM COMPOUNDS; TOXICITY;

CONCURRENCY CONTROL;

CISPLATIN; ERLOTINIB; PACLITAXEL;

ADULT; ADVANCED CANCER; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DRUG ERUPTION; ESOPHAGITIS; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; FEASIBILITY STUDY; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT SATISFACTION; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RELAPSE; SIDE EFFECT; THERAPY EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRACHEITIS; TREATMENT DURATION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; HUMANS; LEUKOPENIA; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RECEPTOR, EPIDERMAL GROWTH FACTOR; THROMBOCYTOPENIA;

EID: 78549279090     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.10.012     Document Type: Article

References (38)

1. D.M. Parkin, F. Bray, and J. Ferlay Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
2. S.S. Devesa, W.J. Blot, and J.F. Fraumeni Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States Cancer 83 1998 2049 2053
3. M. Fok, J.S. Sham, and D. Choy Postoperative radiotherapy for carcinoma of the esophagus: A prospective, randomized controlled study Surgery 113 1993 138 147
4. Medical Research Council Oesophageal Cancer Working Group Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomized controlled trial Lancet 359 2002 1727 1733
5. T.N. Walsh, N. Noonan, and D. Hollywood A comparison of multimodal therapy and surgery for esophageal adenocarcinoma N Engl J Med 335 1996 462 467
6. J.F. Bosset, M. Gignoux, and J.P. Triboulet Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell carcinoma of the esophagus N Engl J Med 337 1997 161 167
7. J.S. Cooper, D. Matthew, and Arnold Herskovic Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospecitve randomized trial (RTOG 85-01) J Am Med Assoc 281 1999 1623 1627
8. H. Kuwano, H. Kato, and T. Miyazaki Genetic alterations in esophageal cancer Surg Today 35 2005 7 18
9. R.S. Herbst, M. Fukuoka, and J. Baselga Gefitinib - a novel targeted approach to treating cancer Natl Rev Cancer 4 2004 956 965
10. N. Balaban, J. Moni, and M. Shannon The effect of ionizing radiation on signal transduction: Antibodies to EGF receptor sensitize A431 cells to radiation Biochim Biophys Acta 1314 1996 147 156
11. P. Chinnaiyan, S. Huang, and G. Vallabhaneni Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Erlotinib) Cancer Res 65 2005 3328 3335
12. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578
13. M.C. Dobelbower, S.M. Russo, and K.P. Raisch Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: A phase I study Anti-Cancer Drugs 17 2006 95 102
14. D.H. Ilson, L. Saltz, and P. Enzinger Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer J Clin Oncol 17 1999 3270 3275
15. E.L. Kaplan, and P. Meier Nonparametric estimation of incomplete observations J Am Stat Assoc 53 1958 457 481
16. P. Zhang, C.Y. Xie, and S.X. Wu Concurrent chemoradiation with paclitaxel and platinum for locally advanced esophageal cancer Zhonghua Zhong Liu Za Zhi 29 2007 773 777
17. D.G. Pfister, Y.B. Su, and D.H. Kraus Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm J Clin Oncol 24 2006 1072 1078
18. C. Rodel, G.G. Grabenbauer, and T. Papadopoulos Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer J Clin Oncol 21 2003 3098 3104
19. D. Herchenhorn, F.L. Dias, and R.M. Pineda Phase II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN) [Abstract] J Clin Oncol 25 Suppl 18 2007 S307
20. A. Ardizzoni, R. Evangelia, and L. Mikhail Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) [Abstract] J Thorac Oncol 2 2007 S342
21. Xu Y, Zhou Y, Huang M, et al. Gefitinib versus platinum contained doublet chemotherapy in chemotherapy-naive patients with stage IIIb or IV non-small cell lung cancer of adenocarcinoma histology: A retrospective case control study [Abstract]. 2009 ASCO Annual Meeting: e19070.
22. C.M. Rudin, W. Liu, and A. Desai Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity J Clin Oncol 26 2008 1119 1127
23. O. Dassonville, J.L. Formento, and M. Francoual Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer J Clin Oncol 11 1993 1873 1878
24. H. Shiozaki Mechanism of the lymph node metastasis in human esophageal cancer (epidermal growth factor causes the dysfunction of cadherinmediated cell-cell adhesion) Hum Cell 9 1996 31 36
25. M. Ueda New prognostic factors in patients with esophageal squamous carcinoma Gan To Kagaku Ryoho 19 1992 20 25
26. Y. Itakura, H. Sasano, and C. Shiga Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification Cancer 74 1994 795 804
27. K. Iihara, H. Shiozaki, and H. Tahara Prognostic significance of transforming growth factor-alpha in human esophageal carcinoma. Implication for the autocrine proliferation Cancer 71 1993 2902 2909
28. S. Ozawa, M. Ueda, and N. Ando Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas Cancer 63 1989 2169 2173
29. M.K. Gibson, S.C. Abraham, and T.T. Wu Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy Clin Cancer Res 9 2003 6461 6468
30. H. Friess, A. Fukuda, and W.H. Tang Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: Overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and cerbB-3 World J Surg 23 1999 1010 1018
31. J.A. Ajani, D.H. Ilson, and K. Daugherty Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus J Natl Cancer Inst 86 1994 1086 1091
32. D.H. Ilson, J. Ajani, and K. Bhalla Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus J Clin Oncol 16 1998 1826 1834
33. J.J. Lokich, H. Sonneborn, and N.R. Anderson Combined paclitaxel, cisplatin and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas Cancer 85 1999 2347 2351
34. B. Brenner, H. IlsonD, and B.D. Minsky Phase I trial of combined-modality therapy for localized esophageal cancer: Escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy J Clin Oncol 22 2004 45 52
35. D.J. Adelstein, T.W. Rice, and L.A. Rybicki Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy J Clin Oncol 18 2000 2032 2039
36. W. Tew, M. Shah, and G. Schwartz Phase II trial of erlotinib for second-line treatment in advanced esophageal cancer [Abstract] Proc Am Soc Clin Oncol GI Cancers Symposium 23 2005 5a
37. D.R. Ferry, M. Anderson, and K. Beddows Phase II trial of gefitinib (ZD1839) in advanced adenocarcinoma of the oesophagus incorporating biopsy before and after gefitinib [Abstract] J Clin Oncol 22 Suppl 14 2004 4021
38. F. Teraishi, S. Kagawa, and T. Watanabe ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma FEBS Lett 579 2005 4069 4075